References
- Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007;369:1641-57. https://doi.org/10.1016/S0140-6736(07)60751-X
- Louis E, Collard A, Oger AF, Degroote E, Aboul Nasr El Yafi FA, Belaiche J. Behaviour of Crohn's disease according to the vienna classification: changing pattern over the course of the disease. Gut 2001;49:777-82. https://doi.org/10.1136/gut.49.6.777
- Thia KT, Sandborn WJ, Harmsen WS, Zinsmeister AR, Loftus EV Jr. Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort. Gastroenterology 2010;139: 1147-55. https://doi.org/10.1053/j.gastro.2010.06.070
- Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9. https://doi.org/10.1016/S0140-6736(02)08512-4
- Sands BE, Blank MA, Patel K, van Deventer SJ; ACCENT II Study. Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study. Clin Gastroenterol Hepatol 2004;2:912-20. https://doi.org/10.1016/S1542-3565(04)00414-8
- Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, et al. Induction and maintenance infliximab therapy for the treatment of moderate- to-severe Crohn's disease in children. Gastroenterology 2007;132:863-73. https://doi.org/10.1053/j.gastro.2006.12.003
- Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol 2011;106:685-98. https://doi.org/10.1038/ajg.2011.103
- Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006;130:323-33. https://doi.org/10.1053/j.gastro.2005.11.030
- Sandborn WJ, Hanauer SB, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh DG, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007;56:1232-9. https://doi.org/10.1136/gut.2006.106781
- Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007;132:52-65. https://doi.org/10.1053/j.gastro.2006.11.041
- Hyams JS, Griffiths A, Markowitz J, Baldassano RN, Faubion WA Jr, Colletti RB, et al. Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children. Gastroenterology 2012;143:365-74.e2. https://doi.org/10.1053/j.gastro.2012.04.046
- Levine A, Koletzko S, Turner D, Escher JC, Cucchiara S, de Ridder L, et al. ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr 2014;58:795-806.
- Levine A, Griffiths A, Markowitz J, Wilson DC, Turner D, Russell RK, et al. Pediatric modification of the montreal classification for inflammatory bowel disease: the paris classification. Inflamm Bowel Dis 2011;17: 1314-21. https://doi.org/10.1002/ibd.21493
- Lee YM, Kang B, Lee Y, Kim MJ, Choe YH. Infliximab "Top-Down" strategy is superior to "Step-Up" in maintaining long-term remission in the treatment of pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2015; 60:737-43. https://doi.org/10.1097/MPG.0000000000000711
- Allez M, Karmiris K, Louis E, Van Assche G, Ben-Horin S, Klein A, et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohns Colitis 2010;4:355-66. https://doi.org/10.1016/j.crohns.2010.04.004
- Rosh JR, Lerer T, Markowitz J, Goli SR, Mamula P, Noe JD, et al. Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn's disease. Am J Gastroenterol 2009;104:3042-9. https://doi.org/10.1038/ajg.2009.493
- Russell RK, Wilson ML, Loganathan S, Bourke B, Kiparissi F, Mahdi G, et al. A british society of paediatric gastroenterology, hepatology and nutrition survey of the effectiveness and safety of adalimumab in children with inflammatory bowel disease. Aliment Pharmacol Ther 2011;33:946-53. https://doi.org/10.1111/j.1365-2036.2011.04603.x
- Cozijnsen M, Duif V, Kokke F, Kindermann A, van Rheenen P, de Meij T, et al. Adalimumab therapy in children with Crohn disease previously treated with infliximab. J Pediatr Gastroenterol Nutr 2015;60:205-10. https://doi.org/10.1097/MPG.0000000000000589
- Fumery M, Jacob A, Sarter H, Michaud L, Spyckerelle C, Mouterde O, et al. Efficacy and safety of adalimumab after infliximab failure in pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2015;60:744-8. https://doi.org/10.1097/MPG.0000000000000713
- Frederiksen MT, Ainsworth MA, Brynskov J, Thomsen OO, Bendtzen K, Steenholdt C. Antibodies against infliximab are associated with de novo development of antibodies to adalimumab and therapeutic failure in infliximab-to-adalimumab switchers with IBD. Inflamm Bowel Dis 2014;20:1714-21. https://doi.org/10.1097/MIB.0000000000000138
- Rutgeerts P, Van Assche G, Sandborn WJ, Wolf DC, Geboes K, Colombel JF, et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology 2012;142:1102-11. https://doi.org/10.1053/j.gastro.2012.01.035
- Jones JL, Kaplan GG, Peyrin-Biroulet L, Baidoo L, Devlin S, Melmed GY, et al. Effects of concomitant immunomodulator therapy on efficacy and safety of anti-tumor necrosis factor therapy for Crohn's disease: a meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2015;13:2233-40. https://doi.org/10.1016/j.cgh.2015.06.034
- Osterman MT, Sandborn WJ, Colombel JF, Robinson AM, Lau W, Huang B, et al. Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease. Gastroenterology 2014;146:941-9. https://doi.org/10.1053/j.gastro.2013.12.025
Cited by
- Effectiveness and safety of adalimumab biosimilar in inflammatory bowel disease: A multicenter study vol.38, pp.1, 2016, https://doi.org/10.1007/s12664-018-0922-1